This is a continuation of the guest series by Drew Waight analyzing NeurogesX for investment.
Last time I covered the therapeutic market area of neuropathic pain, which is NeurogesX’s major area of focus. This time I’ll be doing the due diligence on their first product candidate NGX-4010, and it’s safe to say that the entire company […]

Filed under: NeurogesX (NGSX) | 1 Comment »

This is a guest series from Drew Waight a graduate student at NYU. Leave him a comment if you like his analysis and maybe he’ll send another one in. I should be back in August when I’ve finally made my escape from the lab and no longer have two jobs. Until then, you can catch […]

Filed under: NeurogesX (NGSX) | 3 Comments »